AB-CHMINACA is an indazole-based synthetic cannabinoid (CB) that is structurally related to AB-FUBINACA , a high affinity ligand of the CB1 receptor (Ki = 0.9 nM).[1] [2] MO-CHMINACA is structurally similar to AB-CHMINACA by bearing an identical methylcyclohexyl group; however, the carboxamide-linked aminocarbonyl-2-methylpropyl side chain is substituted with an ester-linked 3,3-dimethylbutyl methyl ester. The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
Reference:
[1]. Uchiyama, N., Matsuda, S., Wakana, D., et al. New cannabimimetic indazole derivatives, N-(1-amino-3methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol. 31(1), 93-100 (2013).
[2]. Buchler, I.P., Hayes, M.J., Hedge, S.G., et al. Indazole derivatives. 1-283 (2009).